As we look towards 2021 and beyond, Deloitte has unveiled ten predictions on how patients, healthcare and life science companies and their staff might behave and operate in five years’ time, based on today’s evidence.
• Advances in AI-enabled robotics, cognitive automation, digitalisation and life-long learning will help task shifting and role-enrichment, changing the who, what, and where of work.
• Advanced AI-enabled technologies will also have accelerated drug discovery and clinical trials improving efficiency and efficacy and reducing costs, enabling companies to reverse the decline in the returns from pharma R&D.
• Predictive prevention models will have led to more precise public health digital interventions – dramatically lowering smoking rates, improving nutrition and reducing loneliness.
Fran Cousins, partner and Deloitte Life Sciences Catalyst lead, said: “This year, inevitably, our predictions have been informed by the unparalleled impact of COVID-19 and how people perceive health risks.
“In response to the pandemic, the pharma industry, academia, biotech and governments initiated scientific ventures funded by governments, multilateral agencies, not-for-profit institutions and the private sector. The sharing of data has expedited the search for new treatments and vaccines, with regulators quickly entering into discussion aimed at supporting the most promising innovations.”
Hanno Ronte, partner, Monitor Deloitte added: “Traditional boundaries are becoming more porous, creating an opportunity for new healthcare behaviours and business and funding models from both incumbents and new entrants.
“We have seen a new public appreciation of the contribution that healthcare and life sciences companies make to each countries’ response to the pandemic. There has also been a huge acceleration in the pace and scale of technology-enabled transformation in ways of working and engaging with patients across the whole health ecosystem that has stood out.”
About Deloitte Life Sciences Catalyst
Developed through our industry understand and deep relationship across the local and global ecosystem, the Deloitte Life Sciences Catalyst exists to solve the business challenges that keep life sciences leaders and innovators up at night.
Via a virtual events programme, a database of whitepapers and a business surgery programme, the Life Sciences Catalyst facilitates connections between people, businesses and investors to support companies, regardless of their evolutionary stage.
Based in the heart of Cambridge, but working virtually, we are ready to help you harness the business opportunities ahead.
Contact us to start the conversation.
In this press release references to “Deloitte” are references to one or more of Deloitte Touche Tohmatsu Limited (“DTTL”) a UK private company limited by guarantee, and its network of member firms, each of which is a legally separate and independent entity.
Please see deloitte.com/about for a detailed description of the legal structure of DTTL and its member firms.
Deloitte LLP is a subsidiary of Deloitte NSE LLP, which is a member firm of DTTL, and is among the UK's leading professional services firms.
The information contained in this press release is correct at the time of going to press.
For more information, please visit www.deloitte.co.uk.
Claire Campbell